2 cheap shares I’d buy following Pfizer’s vaccine breakthrough

I believe these two cheap shares are well positioned following the Pfizer vaccine news and still have plenty of room to run.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The market soared in Monday afternoon trading as Pfizer announced results from its Covid-19 vaccine trial. These proved to be extremely promising and offer a route to re-opening the world economy. This is particularly positive for the UK, where the country has just entered lockdown for the second time – the vaccine announcement has injected optimism around future trading for many shares. Even after the 5% Footsie surge on Monday, I still believe the market has further to go to price in fully the significance of the new vaccine. The UK market is full of promising cheap shares at present, many of whom I believe are seriously undervalued.

Hollywood Bowl offers plenty of potential

The first cheap share I’m interested in buying more of is Hollywood Bowl (LSE:BOWL). I believe there is much appeal to Hollywood Bowl at current levels as the leading bowling alley operator in the UK. The company is desperate for some way out of this pandemic and the new vaccine may have just provided that.

Even after the recent c.45% surge in share price, shares still stand down around 35% since late February. Prior to the pandemic, Hollywood Bowl was performing very well and delivered increasingly strong financial results. Full year 2019 revenues had increased 7.8% year-on-year and profit before tax was up 15% to £27 million. The company had even taken action to trim its already low debt by 15% to £2.1 million.

It was no surprise, then, to see that Hollywood Bowl’s share price was hitting all-time highs before Covid gripped the market. I believe there is still a strong market position for the company in the post-Covid world, where consumers will be seeking post-lockdown entertainment. With a historic P/E of just 10, I believe Hollywood Bowl is an attractive cheap share for the post-vaccine world, and am pleased to see that my Foolish colleague Roland Head agrees.

Why Everyman looks like a cheap share

The other share on my list is the niche cinema chain Everyman Media Group (LSE:EMAN). Everyman has a fascinating business model with a fresh, revolutionary offering. The cinema chain places a focus on quality of experience in each of its venues and therefore charges a higher price for tickets. Everyman wants to curate this experience for cinema-goers through a greater emphasis on comfort and quality of food and drink to attract a higher spending up-market clientele.

Like Hollywood Bowl, Everyman was performing well before the pandemic, steadily growing both its top and bottom line with a programme of new cinema roll-outs. Due to the pandemic, the cinema industry was one of the hardest hit – but this has put Everyman at a favourable valuation currently. Even through the pandemic, I favoured Everyman as it has fewer cinemas and is therefore far more versatile than peers such as Cineworld that have higher fixed costs.

Unlike Cineworld, Everyman only closed its cinemas when forced to do so by government guidelines. The new vaccine promise has given Everyman shares relief, surging around 35% from their recent lows. However, even after this rise, I believe Everyman is a cheap share at current levels. Whilst the P/E is higher than Hollywood Bowl’s, this a high-growth, exciting, niche-focused firm. I believe Everyman’s historic P/E of less than 40 is cheap, particularly with the strong vaccine potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Noah Riley owns shares in Hollywood Bowl and Everyman Media Group. The Motley Fool UK has recommended Hollywood Bowl. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

Up 20% with a 9% yield! This stock remains my top passive income earner

When it comes to earning passive income through dividend investing, this major FTSE 100 insurer is the undeniable winner in…

Read more »

4 Teslas in a parking lot at a charger station
Investing Articles

Tesla vs Ferrari: which stock is leading the race in 2025?

This writer digs into the Q1 numbers to see whether his decision to choose Ferrari over Tesla stock has been…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

Here’s the growth forecasts for Next shares through to 2028!

Next's shares have risen in price again after another forecast-raising trading statement. Is the FTSE 100 company a white hot…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Up 145%, this investment trust has a P/E ratio of 10. Is it still a bargain?

The long-term track record of this investment trust has been excellent. Our writer thinks it could still be a bargain…

Read more »

Bournemouth at night with a fireworks display from the pier
Investing Articles

These 3 dividend shares are on fire but they’re still dirt-cheap and pay piles of income!

Harvey Jones is hugely impressed by 3 FTSE 100 dividend shares that have managed to deliver on two key fronts,…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

9% yield! Is this one of the best dividend stocks to consider buying right now?

With signs the worst for it might be over, dividend investors should add B&M European Value to their lists of…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Down 26% in 3 months! What’s going on with the Alphabet share price?

Stock market investors sold off Alphabet (NASDAQ:GOOG) shares heavily yesterday. Is this a worry or a timely buying opportunity to…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Here’s why the Next share price is rising again today

The Next share price keeps climbing, but should investors like me consider buying? Roland Head looks at today’s news and…

Read more »